Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II tislelizumab monotherapy in hepatocellular carcinoma with Child-Pugh B liver function
2020-003108-15Phase 2Active
- Sponsor
- Unicancer
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by Unicancer. Primary endpoint: Objective Response Rate. Started Aug 2022; status: active.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2020-003108-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003108-15.